Targeting chaperone-mediated autophagy inhibits properties of glioblastoma stem cells and restores anti-tumor immunity
Ontology highlight
ABSTRACT: Chaperone-mediated autophagy (CMA), a selective autophagic process, plays a crucial role in maintaining intracellular quality and facilitating cellular responses to stress. While CMA has been implicated in finely regulating the stemness of normal stem cells, its significance in cancer stem cells (CSCs) remains largely undefined. In this study, we demonstrate that CMA is upregulated in patient-derived glioblastoma stem cells (GSCs), characterized by a notable increase in the levels of the CMA receptor, lysosome-associated membrane protein type 2A (LAMP2A). The enhanced stability of LAMP2A within GSC lysosomes is a result of MST4-mediated phosphorylation at residues T40, S97, and T136, which facilitates LAMP2A homotrimer formation and diminishes LAMP2A degradation by obstructing the interaction between LAMP2A and Cathepsin A. The contribution of CMA to the self-renewal and tumorigenic potential of GSCs is mediated by the upregulation of mTORC1 activity through the selective lysosomal degradation of its two negative modulators, TSC1 and TSC2. Furthermore, CMA is implicated in promoting resistance to immunotherapy in GBM by inhibiting the TET3-dependent enhancement of tumor cGAS and STING expression. Finally, the genetic or pharmacological inhibition of CMA exhibits a synergistic effect with immune checkpoint therapy in murine models of GBM. Our findings delineate an MST4-LAMP2A signaling pathway that modulates CMA activity and the malignancy of GSCs, with therapeutic targeting of this axis potentially overcoming immunotherapy resistance in GBM.
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Kidney Epithelium
DISEASE(S): Brain Cancer
SUBMITTER:
Yonghua Li
LAB HEAD: Tianzhi Huang
PROVIDER: PXD060464 | Pride | 2025-09-22
REPOSITORIES: Pride
ACCESS DATA